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Abstract 
The present work describes preparation, structural and morphological characterization of PHEMA nanoparticles. It is 
found that the nanoparticles are having size up to 100 nm and are almost identical in shape. The small size of 
nanoparticles makes them a suitable candidate for biomedical and pharmaceutical applications especially to 
controlled drug delivery field.  
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Introduction 
The number of reported cases of cancer is steadily increasing in both industrialized and developing countries. The 
latest world cancer statistics indicate that the number of new cancer cases will increase to more than 15 million in 
2020 whereas another report issued by the World Health organization says that there are over 10 million new cases 
of cancer each year and over 6 million deaths annually are caused by the disease [1]. In spite of the fact that 
significant progress has been achieved in tumor biology, molecular genetics and in the prevention, detection and 
treatment of cancer over the last few years, adequate therapy remains elusive due to late diagnosis, inadequate 
strategies for addressing aggressive metastasis, and the lack of clinical procedures overcoming multi drug resistant 
(MDR) cancer [2]. The integration of nanotechnology and medicine has the potential to uncover the structure and 
function of biosystems at the nanoscale level. Nanobiotechnology may provide a reliable and effective tool to treat 
diseases at a molecular scale. Nanobiotechnology offers an unprecedented opportunity to rationalize delivery of 
drugs and genes to solid tumors following systemic administration [3]. Examples of nanotechnologies applied in 
pharmaceutical product development include polymer-based nanoparticles, lipid-based nanoparticles (liposomes, 
nanoemulsions, and solid-lipid nanoparticles), self-assembling nanostructures such as micelles and dendrimers-based 
nanostructures among others. In recent years, much research has gone into the characterization of nanoparticles and 
their biological effects and potential applications. These include bottom-up and molecular self-assembly, biological 
effects of naked nanoparticles and nano-safety, drug encapsulation and nanotherapeutics, and novel nanoparticles for 
use in microscopy, imaging and diagnostics [4]. 
To be successful a cancer treatment approach needs to overcome physiological barriers such as vascular endothelial 
pores, heterogeneous blood supply, heterogeneous architecture to name just a few and it strongly depends on the 
method of delivery. In the past, many anticancer drugs had only limited success and had major adverse side effects. 
Nanoparticles have attracted considerable attention worldwide because of their unique functional characters such as 
small particle size, high stability, lower toxicity, tunable hydrophilic-hydrophobic balance and the ability to bear 
surface features for target specific localization, etc. Thus, polymeric nanoparticles constitute a versatile drug delivery 
system , which can potentially overcome physiological barriers, and carry the drug to specific cells or intracellular 
compartments by passive or ligand-mediated targeting approaches. The use of some polymers also allows, at least in 
principle, to achieve controlled release and the sustained drug levels for longer periods of time. Numerous 
biodegradable polymeric nanoparticles made of natural polymers such as proteins or polysaccharides have been tried 
for drug delivery and controlled drug release. More recently the focus of such studies moved onto synthetic polymers, 
and much progress have been achieved in this area. Recent examples include, for example polycationic nanoparticles 
for encapsulation and controlled release of amphotericin B by Vieria and Carmona-Ribeiro ; or encapsulation of cur 
cumin for human cancer therapy by Maitra et al. 
Ideally, a successful nanoparticulate system should have a high drug loading capacity thereby reducing the quantity 
of matrix material for administration. The drug may be bound to the nanoparticles either (i) by polymerization in the 
presence of drug in most cases in the form of solution (incorporation method) or (ii) by absorbing/adsorbing the drug 
after the formation of nanoparticles by incubating them in the drug solution. In the present work we set to further 
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investigate the latter method by studying swelling and controlled release of antitumor drug doxorubicin from 
synthetic PHEMA nanoparticles. PHEMA attracted significant attention and is well documented in the literature. 
Many useful properties which make PHEMA attractive for a wide range of biomedical applications include high 
water content, low toxicity and tissue compatibility. PHEMA has been used in applications such as soft contact 
lenses, drug delivery systems, kidney dialysis membranes, artificial liver support systems and nerve guidance 
channels. The presence of polar groups of hydroxyl and carboxyl on each repeat unit makes this polymer compatible 
with water and the hydrophobic α-methyl groups of the backbone convey hydrolytic stability to the polymer and 
enhance mechanical strength of the polymer matrix. The drug chosen for this study was doxorubicin hydrochloride, 
which belongs to the family of anti-tumor drugs(Fig.1).. Doxorubicin is a cytotoxic anthracycline antibiotic, it is 
widely used in the treatment of non-Hodkin's lymphoma, acute lymphoblastic leukemia, breast carcinomas and 
several other types of cancer. We aimed to design a better PHEMA nanoparticulate delivery system for clinical 
administration of doxorubicin to achieve higher therapeutic efficacy and reduce side effects, with the overall aim to 
develop effective oral chemotherapy system. 
 
Materials 
2-Hydroxyethyl methacrylate (HEMA) and ethylene glycol dimethacrylate (EGDMA) were purchased from Sigma 
Aldrich Co. USA. Benzoyl peroxide (BPO) (MERCK) and polyvinyl alcohol (PVA) (Mol. Wt. 14000) (MERCK) 
were used as the initiator and the stabilizer, respectively. Toluene (MERCK) was used as the diluent. All chemicals 
were of analytical grade. 
 
 Methods 
Purification of HEMA 
HEMA monomer was purified by using a previously reported method [5]. The purity of distilled HEMA was 
determined by high-pressure liquid chromatography (HPLC), [Backmen System (Gold 127)] equipped with a 
ultraviolet detector and a 25 cm × 46 mm id separation columns ODS (C18) of 5 µm particle size. The UV detector 
was set at 217 nm. The mobile phase was methanol-water (60:40 v/v) and the flow-rate was kept at 1 mL/min. All 
samples were diluted with pure methanol to 1/1600. 10 µL samples were injected for each analysis. Samples of 
known concentrations of MAA and EGDMA were injected into the HPLC and the resultant chromatogram was used 
to construct a standard curve of known concentrations vs. area under the curve. The chromatogram showed two 
distinct peaks. The first peak, at 3.614 min was identified as MAA. The next peak at 5.503 min was the major peak 
due to HEMA monomer. The amounts of impurities of MAA and EGDMA in the monomer samples were found to 
be less than 0.01 mol% MAA and 0.001 mol% EGDMA. 
 
Preparation of PHEMA Nanoparticles 
Preparative methods for making nanoparticles for pharmaceutical use are broadly divided into two categories, those 
based on physiochemical properties such as phase separation and solvent evaporation, and chemical reactions such as 
polymerization, and polycondensation. In the present study cross-linked PHEMA nanoparticles of defined 
composition were prepared by using a modified suspension polymerization technique.. In particular, the 
polymerization was carried out in an aqueous phase containing PVA, which was used as the stabilizing agent. The 
mixture containing the 12.37 mM HEMA (the monomer), 1.06 mM EGDMA (the cross-linker) and 0.248 mM 
Bz2O2 (the initiator) dispersed in toluene was added into 500 mL conical flask containing the suspension medium 
(200 mL aqueous PVA solution (0.5% W/V)). The reaction mixture was flushed by bubbling nitrogen and then 
sealed. The reaction mixture was then placed on magnetic stirrer and heated by vigorous stirring (600-700 rpm) at 
80°C for 2 h and then at 90°C for 1 h. The cross-linking reaction was completed within three hours. After cooling, 
the polymeric particles were separated from the polymerization medium by washing thrice with toluene and twice 
with acetone. The collected nanoparticles were dried at room temperature to obtain the fine white powder and 
thereafter stored in airtight polyethylene bags. Doubly distilled water was used throughout the experiments. 
 
Characterization 
1.IR Studies 
The IR spectra of cross-linked PHEMA nanoparticles were recorded on a FTIR spectrophotometer (Perkin-Elmer, 
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1000 Paragon) (Shimadzu). While recording FTIR spectra KBr disc method was used for preparation of samples. 
2.SEM and Particle Size Analysis 
Morphological studies of cross-linked PHEMA nanoparticles were performed on scanning electron micrographs 
(SEM). SEM observations were carried out with a Philips, 515, fine coater. Drops of the polymeric nanoparticles 
suspension were placed on a graphite surface and freeze dried. The sample was then coated with gold by ion sputter. 
The coating was performed at 20 mA for 4 min, and observation was made at 10 KV. Nanoparticles were further 
characterized by particle size analysis for size and size distribution. The particle size analysis of prepared 
nanoparticles was performed on a particle size analyzer (Malvern Mastersizer 2000). 
Zeta potential studies were performed with a digital potentiometer (Model No. 118, EI Product, Mumbai, India). In a 
typical experiment 0.1 g nanoparticles were dispersed in 20 mL of respective pH solution and emf was recorded 
using a compound electrode system. A similar experiment was also repeated for drug-loaded nanoparticles. 
 
Results and Discussion 
The FTIR spectra of the pure drug (doxorubicin) and loaded nanoparticles are shown in Fig. 2(a) and 2(b), 
respectively. The IR spectra (b) of loaded nanoparticles clearly indicate the presence of HEMA as evident from the 
observed bands at 1728 cm
-1 
(C=O stretching), 1172 cm
-1 
(O-C-C stretching), 3556 cm
-1 
(O-H stretching), 2951 cm
-
1 
(asymmetric stretching of methylene group) and 1454 cm
-1 
(O-H bending) respectively. The spectra (b) also mark 
the presence of drug (doxorubicin) as evident from the observed bands at 1000-1260 cm
-1 
(C-O stretching of alcohol) 
and 675-900 cm
-1 
(out of plane O-H bending). The resemblance of spectra shown in Fig. 2(a) (the pure drug) and in 
Fig. 2(b) (loaded nanoparticles) confirms the presence of drug in the loaded nanoparticles. 
 
Figure 1 FTIR spectra of PHEMA nanoparticles 
 
SEM Analysis and Particle Size Analysis 
The SEM image of nanoparticles is shown in Fig. 2(a), which also reveals the morphology of PHEMA nanoparticles. 
The size of nanoparticles was estimated using SEM images. Under our experimental conditions it has been shown to 
vary between 100 and 300 nm. The particle size distribution curve of prepared nanoparticles is shown in Fig. 2(b). 
The small (defined) size of the nanocarriers’ results in the increased surface to volume ratio [20], enhanced frictional 
forces as well as adsorption. These properties allow nanoparticles to be held in suspension and largely define their 
biological fate, toxicity and targeting ability, as well as drug loading potential, their stability and drug release 
properties. The interaction of nanoparticles with living systems depends on their characteristic dimensions. 
Previously published studies proved the ability of ultra small nanoparticles to translocate throughout the body (see ξ-
Potential is the difference in the electrical charge developed between the dense layers of ions surrounding the 
particles and the charge of the bulk of the suspended fluid surrounding the particle; it gives information about the 
overall surface charge of the particles. 
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Figure 2 SEM image and particle size distribution curve of PHEMA nanoparticles 
Conclusions 
The prepared nanoparticles of PHEMA are will within 100 nm and may be employed as carrier for controlled 
delivery of anticancer and antitumor drugs.  
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